H.C. Wainwright reiterates Legend Biotech stock rating at buy

H.C. Wainwright reiterated a Buy rating on Legend Biotech with a $50 price target, implying material upside from the current $27.16 share price. The firm highlighted long-term CARVYKTI data, first-relapse use potential, and a new China Phase 1 study for LVIVO-TaVec400, supporting the company’s in vivo CAR-T platform. Recent Q1 2026 results were mixed, with EPS of -$0.15 versus $0.01 expected and revenue of $305.1M versus $305.88M consensus, but investors remain focused on the pipeline and profitability outlook.

Analysis

The key incremental takeaway is not the near-term sell-side reiteration; it is the widening gap between clinical conviction and financial skepticism. If first-relapse adoption of cilta-cel accelerates, the market is underestimating how quickly the addressable population shifts from a later-line salvage pool into a much larger, higher-fit earlier-line segment, which should lift both utilization and manufacturing efficiency. That matters because a one-time cell therapy with stronger durability can behave more like a platform franchise than a single product, making the valuation multiple sensitive to confidence in long-term remission rather than quarterly EPS noise.

The second-order winner is likely the broader CAR-T ecosystem: collection, logistics, bridging therapy, and treatment-center capacity all benefit if earlier-line referral becomes standard practice. The loser is the category of therapies that depend on prolonged treatment duration in first relapse, especially regimens that compete on convenience rather than durability. A meaningful risk is that safety management and manufacturing throughput, not efficacy, become the gating factor; if earlier use expands before center readiness catches up, adoption can bottleneck even with strong clinical data.

The contrarian read is that the market may be over-focusing on the earnings miss and underpricing the optionality from the autoimmune/in vivo CAR-T angle. That program is still early, but it expands the valuation framework beyond myeloma and gives the stock a second shot at re-rating if in vivo delivery starts to look clinically scalable. The near-term catalyst path is clearer than usual: any evidence of accelerating first-relapse referrals, improved manufacturing consistency, or durable signal from the autoimmune study can shift the stock over a 1-3 month horizon, while downside comes if investors conclude the story remains scientifically exciting but commercially slow to convert.

Key Decisions for Investors

• Initiate a tactical long in LEGN ahead of the next clinical/data read-through, targeting a 6-10 week horizon; use the current post-earnings dislocation as entry if volume stabilizes. Upside is a sentiment re-rating toward the sell-side range; downside is capped by positioning if adoption commentary disappoints.
• Prefer a call spread in LEGN over outright stock for the next 1-3 months to isolate re-rating potential from earnings volatility; structure around the next conference or KOL/data event. This gives favorable convexity if first-relapse adoption commentary drives multiple expansion.
• Pair trade: long LEGN / short a later-line myeloma therapy proxy or basket to express migration toward earlier-line durable treatment. The thesis is that the market will reward duration and one-time consolidation, while chronic-treatment competitors face slower growth multiples.
• Watch for confirmation in center-level adoption metrics and manufacturing cadence; if either fails to improve over the next quarter, reduce exposure quickly. The trade works only if the market believes operational execution can keep pace with clinical enthusiasm.